ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II

Prajnan Das; Andrea Ng; Louis S. Constine; Ranjana Advani; Christopher Flowers; Jonathan Friedberg; David C. Hodgson; Cindy L. Schwartz; Richard B. Wilder; Lynn D. Wilson; Michael J. Yunes

doi:10.1016/j.jacr.2011.01.009

ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II

Prajnan Das, Andrea Ng, Louis S. Constine, Ranjana Advani, Christopher Flowers, Jonathan Friedberg, David C. Hodgson, Cindy L. Schwartz, Richard B. Wilder, Lynn D. Wilson, Michael J. Yunes

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Combined-modality therapy, consisting of chemotherapy followed by radiation therapy (RT), represents the standard of care for most patients with unfavorable-prognosis early-stage Hodgkin's lymphoma. The most widely accepted chemotherapy regimen is ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine); however, recent trials have evaluated other regimens such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and Stanford V. After chemotherapy, the standard radiation field is involved-field RT, although there is increasing interest now in involved-node RT. The authors review recent trials on chemotherapy and RT for unfavorable-prognosis early-stage Hodgkin's lymphoma. This article presents illustrative clinical cases, with treatment recommendations from an expert panel of radiation oncologists and medical oncologists.

Original language	English (US)
Pages (from-to)	302-308
Number of pages	7
Journal	Journal of the American College of Radiology
Volume	8
Issue number	5
DOIs	https://doi.org/10.1016/j.jacr.2011.01.009
State	Published - May 2011

Keywords

Appropriateness Criteria®
Hodgkin's lymphoma
chemotherapy
radiation therapy
unfavorable prognosis

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.jacr.2011.01.009

Cite this

@article{b7bcaf21cc29478b8bad44697bfcbfba,

title = "ACR Appropriateness Criteria{\textregistered} on Hodgkin's lymphoma-unfavorable clinical stage I and II",

abstract = "Combined-modality therapy, consisting of chemotherapy followed by radiation therapy (RT), represents the standard of care for most patients with unfavorable-prognosis early-stage Hodgkin's lymphoma. The most widely accepted chemotherapy regimen is ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine); however, recent trials have evaluated other regimens such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and Stanford V. After chemotherapy, the standard radiation field is involved-field RT, although there is increasing interest now in involved-node RT. The authors review recent trials on chemotherapy and RT for unfavorable-prognosis early-stage Hodgkin's lymphoma. This article presents illustrative clinical cases, with treatment recommendations from an expert panel of radiation oncologists and medical oncologists.",

keywords = "Appropriateness Criteria{\textregistered}, Hodgkin's lymphoma, chemotherapy, radiation therapy, unfavorable prognosis",

author = "Prajnan Das and Andrea Ng and Constine, {Louis S.} and Ranjana Advani and Christopher Flowers and Jonathan Friedberg and Hodgson, {David C.} and Schwartz, {Cindy L.} and Wilder, {Richard B.} and Wilson, {Lynn D.} and Yunes, {Michael J.}",

year = "2011",

month = may,

doi = "10.1016/j.jacr.2011.01.009",

language = "English (US)",

volume = "8",

pages = "302--308",

journal = "Journal of the American College of Radiology",

issn = "1546-1440",

publisher = "Elsevier BV",

number = "5",

}

TY - JOUR

T1 - ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II

AU - Das, Prajnan

AU - Ng, Andrea

AU - Constine, Louis S.

AU - Advani, Ranjana

AU - Flowers, Christopher

AU - Friedberg, Jonathan

AU - Hodgson, David C.

AU - Schwartz, Cindy L.

AU - Wilder, Richard B.

AU - Wilson, Lynn D.

AU - Yunes, Michael J.

PY - 2011/5

Y1 - 2011/5

N2 - Combined-modality therapy, consisting of chemotherapy followed by radiation therapy (RT), represents the standard of care for most patients with unfavorable-prognosis early-stage Hodgkin's lymphoma. The most widely accepted chemotherapy regimen is ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine); however, recent trials have evaluated other regimens such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and Stanford V. After chemotherapy, the standard radiation field is involved-field RT, although there is increasing interest now in involved-node RT. The authors review recent trials on chemotherapy and RT for unfavorable-prognosis early-stage Hodgkin's lymphoma. This article presents illustrative clinical cases, with treatment recommendations from an expert panel of radiation oncologists and medical oncologists.

AB - Combined-modality therapy, consisting of chemotherapy followed by radiation therapy (RT), represents the standard of care for most patients with unfavorable-prognosis early-stage Hodgkin's lymphoma. The most widely accepted chemotherapy regimen is ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine); however, recent trials have evaluated other regimens such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and Stanford V. After chemotherapy, the standard radiation field is involved-field RT, although there is increasing interest now in involved-node RT. The authors review recent trials on chemotherapy and RT for unfavorable-prognosis early-stage Hodgkin's lymphoma. This article presents illustrative clinical cases, with treatment recommendations from an expert panel of radiation oncologists and medical oncologists.

KW - Appropriateness Criteria®

KW - Hodgkin's lymphoma

KW - chemotherapy

KW - radiation therapy

KW - unfavorable prognosis

UR - http://www.scopus.com/inward/record.url?scp=84928099360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928099360&partnerID=8YFLogxK

U2 - 10.1016/j.jacr.2011.01.009

DO - 10.1016/j.jacr.2011.01.009

M3 - Review article

C2 - 21531305

AN - SCOPUS:84928099360

SN - 1546-1440

VL - 8

SP - 302

EP - 308

JO - Journal of the American College of Radiology

JF - Journal of the American College of Radiology

IS - 5

ER -

ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this